UT Southwestern Medical Center
Hematology and Oncology fellowship · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas Southwestern Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About The University of Texas Southwestern Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from The University of Texas Southwestern Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
366
works per year
11th of 74 hematology and oncology fellowship programs
+9.2%
2-year growth
42nd of 74 hematology and oncology fellowship programs
29.3%
in top 10% of field (works before 2025)
16th of 72 hematology and oncology fellowship programs
48.8%
cited above world average
16th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 1,287Hematology · 567
Hematology and Oncology research topics at The University of Texas Southwestern Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 251
- Acute Myeloid Leukemia Research 218
- Pancreatic and Hepatic Oncology Research 140
- Multiple Myeloma Research and Treatments 122
- CAR-T cell therapy research 122
- Cutaneous Melanoma Detection and Management 68
- Renal cell carcinoma treatment 60
- Cancer survivorship and care 59
Most cited at The University of Texas Southwestern Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 312
- Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancerMoumita Kundu et al. · Molecular Cancer · 2024 · PubMed · cited 273
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 243
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta et al. · New England Journal of Medicine · 2024 · PubMed · cited 240
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialNizar M. Tannir et al. · Annals of Oncology · 2024 · PubMed · cited 236
- Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancerStephen Lawrence Shiao et al. · Cancer Cell · 2024 · PubMed · cited 212
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y. Nabet et al. · Cancer Cell · 2024 · PubMed · cited 196
- The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney TransplantationCamille N. Kotton et al. · Transplantation · 2024 · PubMed · cited 195
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024Susan M. Swetter et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 173